Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention

Table 2

Clinical, laboratory, and procedural characteristics in patients with and without MACCEs.

	MACCE-free ()	MACCE ()	value
Clinical characteristics
Age (years)	67 (59-74)	69 (59-76)	0.215
Male, (%)	679 (78.14)	81 (70.43)	0.064
BMI			0.099
SBP (mmHg)	130 (120-144)	128 (119-142)	0.239
DBP (mmHg)	80 (70-86)	75 (68-83)	0.016
LVEF (%)	63 (56-68)	63 (55-69)	0.697
Laboratory characteristics
FBG (mmol/l)	5.64 (5.01-6.82)	5.54 (4.95-6.58)	0.437
TG (mmol/l)	1.35 (0.98-1.94)	1.44 (1.10-2.00)	0.171
TC (mmol/l)	4.34 (3.62-5.21)	4.38 (3.48-5.46)	0.772
LDL-c (mmol/l)	2.85 (2.23-3.62)	2.96 (2.22-3.85)	0.517
HDL-c (mmol/l)	1.01 (0.85-1.21)	1.04 (0.86-1.19)	0.727
BUN (mmol/l)	4.90 (4.10-6.00)	5.20 (4.10-6.10)	0.162
Cre (μmol/l)	77 (67-91)	76 (69-87)	0.891
CK-MB (U/l)	15.30 (11.60-22.90)	16.10 (12.00-69.20)	0.096
UA (μmol/l)	352 (295-417)	355 (300-420)	0.823
NT-proBNP (ng/l)	237 (69-831)	206 (51-921)	0.319
Hs-CRP (mg/l)	3.17 (0.96-8.73)	2.61 (0.98-11.10)	0.715
Hcy (μmol/l)	9.36 (7.70-11.75)	9.18 (7.75-11.42)	0.870
sLOX-1 (ng/ml)	1.00 (0.67-1.77)	1.38 (0.90-2.16)^†	<0.001
Cardiovascular risk factors
Smoking, (%)	417 (47.99)	61 (50.04)	0.308
DM, (%)	280 (32.22)	36 (31.30)	0.843
Hypertension, (%)	548 (63.06)	67 (58.26)	0.318
ACS, (%)	669 (76.99)	99 (86.09)	0.027
Cardiovascular medication
Aspirin, (%)	853 (98.16)	114 (99.13)	0.452
Clopidogrel, (%)	782 (89.99)	102 (88.70)	0.666
Ticagrelor, (%)	86 (9.90)	13 (11.30)	0.637
Statins, (%)	852 (98.04)	112 (97.39)	0.641
ACEI/ARB, (%)	621 (71.46)	88 (76.52)	0.256
Beta-blocker, (%)	690 (79.40)	90 (78.26)	0.777
Procedural characteristics
Number of affected segments	2 (1-3)	2 (1-4)	0.071
Left main disease, (%)	50 (5.75)	14 (12.17)^†	0.009
Multivessel disease, (%)	466 (53.62)	70 (60.87)	0.143
Stents per procedure	2 (1-2)	2 (1-2)	0.117
Small-caliber stents used, (%)	222 (25.65)	40 (33.61)	0.035
Total stent length (mm)	30 (23-54)	38 (33-66)^†	<0.001
Pre-PCI stenosis (%)	90 (85-100)	90 (80-100)	0.467
Post-PCI stenosis (%)	0 (0-0)	0 (0-0)	0.414
Initial TIMI flow	3 (2-3)	3 (1-3)	0.449
Final TIMI flow	3 (3-3)	3 (3-3)	0.407
Chronic total occlusion lesion, (%)	103 (11.85)	15 (13.04)	0.712
Bifurcation lesion, (%)	89 (10.24)	9 (7.83)	0.416

All values are presented as median value (interquartile range) or (%). BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, LVEF = left ventricular ejection fraction, FBG = fasting glucose, TG = triglycerides, TC = total cholesterol, LDL-c = low-density lipoprotein cholesterol, HDL-c = high-density lipoprotein cholesterol, BUN = blood urea nitrogen, Cre = creatinine, CK-MB = creatine kinase-MB, UA = uric acid, NT-proBNP = N-terminal probrain natriuretic peptide, Hs-CRP = high-sensitivity C-reactive protein, Hcy = homocysteine, sLOX-1 = soluble lectin-like oxidized low-density lipoprotein receptor-1, DM = diabetes mellitus, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker, PCI = percutaneous coronary intervention, TIMI = thrombolysis in myocardial infarction. Other abbreviations are shown in Table 1. compared to patients without events, compared to patients without events.